A Vaccine Based on Kunitz-Type Molecule Confers Protection Against Fasciola hepatica Challenge by Inducing IFN-γ and Antibody Immune Responses Through IL-17A Production

SILVANE, LEONARDO; CELIAS, DAIANA PAMELA; ROMAGNOLI, PABLO ALBERTO; MALETTO, BELKYS ANGÉLICA; SANCHEZ VALLECILLO, MARÍA FERNANDA; CHIAPELLO, LAURA SILVINA; PALMA, SANTIAGO DANIEL; ALLEMANDI, DANIEL ALBERTO; SANABRIA, RODRIGO EDUARDO FABRIZIO; PRUZZO, CÉSAR IVÁN; MOTRÁN, CLAUDIA CRISTINA; CERVI, LAURA

Frontiers in Immunology

Frontiers Media S.A.

Año: 2020 vol. 11

asciola hepatica is helminth parasite found around the world that causes fasciolosis, a chronic disease affecting mainly cattle, sheep, and occasionally humans. Triclabendazole is the drug of choice to treat this parasite. However, the continuous use of this drug has led to the development of parasite resistance and, consequently, the limitation of its effectiveness. Hence, vaccination appears as an attractive option to develop. In this work, we evaluated the potential of F. hepatica Kunitz-type molecule (FhKTM) as an antigen formulated with a liquid crystal nanostructure formed by self-assembly of 6-O-ascorbyl palmitate ester (Coa-ASC16) and the synthetic oligodeoxynucleotide containing unmethylated cytosine-guanine motifs (CpG-ODN) during an experimental model of fasciolosis in mice, and we further dissected the immune response associated with host protection. Our results showed that immunization of mice with FhKTM/CpG-ODN/Coa-ASC16 induces protection against F. hepatica challenge b